

Supplementary Table 1. Baseline characteristics for participants with and without reperfusion treatment, before and after propensity score matching.

	Unmatched				Matched			
	No Reperfusion treatment (n=3004)	Reperfusion treatment (n=1225)	P-value	SMD	No Reperfusion treatment (n=936)	Reperfusion treatment (n=936)	P-value	SMD
Cohort			<0.001	1.025			0.21	0.158
Austria	357 (12%)	102 (8%)			110 (12%)	94 (10%)		
Germany (1)	123 (4%)	59 (5%)			60 (6%)	52 (6%)		
Germany (2)	238 (8%)	73 (6%)			69 (7%)	66 (7%)		
Italy	388 (13%)	11 (1%)			18 (2%)	11 (1%)		
Portugal	50 (2%)	101 (8%)			50 (5%)	68 (7%)		
Spain	259 (9%)	252 (21%)			153 (16%)	164 (18%)		
Switzerland (1)	1061 (35%)	139 (11%)			167 (18%)	137 (15%)		
Switzerland (2)	528 (18%)	488 (40%)			309 (33%)	344 (37%)		
Age	74 (62-81)	72 (62-80)	0.01*	0.088	73 (61-82)	72 (61-80)	0.02	0.083
Sex (Male)	1689 (56%)	703 (58%)	0.20	0.055	536 (58%)	560 (60%)	0.26	0.052
NIHSS at admission								
0-3	1655 (55%)	143 (12%)	Ref.	Ref.	149 (16%)	143 (15%)	Ref-	Ref-
4-10	919 (31%)	516 (42%)	<0.001	0.241	466 (50%)	445 (48%)	0.33	0.045
≥11	430 (14%)	566 (46%)	<0.001	0.740	321 (34%)	348 (37%)	0.19	0.060
Stroke etiology								
Large-artery atherosclerosis	522 (17%)	270 (22%)	<0.001	0.117	207 (22%)	204 (22%)	0.87	0.008
Small-vessel occlusion	766 (26%)	103 (8%)	<0.001	0.468	94 (10%)	97 (10%)	0.82	0.011
Cardioembolic	845 (28%)	434 (35%)	<0.001	0.157	343 (37%)	326 (35%)	0.41	0.038
Stroke location								
MCA territory	1947 (65%)	965 (79%)	<0.001	0.314	693 (74%)	708 (76%)	0.42	0.038
ACA territory	142 (4.7%)	74 (6%)	0.092	0.058	53 (5.7%)	47% (5%)	0.54	0.028
PCA territory	705 (23.5%)	321 (26.2%)	0.065	0.063	235(25.1%)	240 (25.6%)	0.79	0.012
Cortical involvement	1405 (47%)	705 (57%)	<0.001	0.217	536 (57%)	531 (57%)	0.81	0.011
ASM treatment after ASS	108 (4%)	82 (7%)	<0.001	0.141	64 (7%)	54 (6%)	0.34	0.044

NIHSS = National Institutes of Health Stroke Scale; MCA = middle cerebral artery; ACA = anterior cerebral artery; PCA = posterior cerebral artery; ASM = anti-seizure medication; ASS = acute symptomatic seizure; SMD = standardized mean difference; * p-value is for Wilcoxon rank-sum test

Supplementary Table 2. Baseline characteristics for participants with IV thrombolysis and without reperfusion treatment, before and after propensity score matching.

	Unmatched				Matched			
	No reperfusion treatment (n=2766)	IV Thrombolysis (n=955)	P-value	SMD	No reperfusion treatment (n=824)	IV Thrombolysis (n=824)	P-value	SMD
Cohort			<0.001	0.988			0.446	0.177
Austria	357 (13%)	100 (11%)			117 (14%)	100 (12%)		
Germany (1)	123 (5%)	43 (5%)			49 (9%)	41 (8%)		
Italy	388 (14%)	11 (1%)			13 (2%)	11 (1%)		
Portugal	50 (2%)	101 (11%)			50 (6%)	74 (9%)		
Spain	259 (9%)	236 (25%)			150 (18%)	185(23%)		
Switzerland (1)	1061 (38%)	139 (15%)			161 (20%)	139 (17%)		
Switzerland (2)	528 (19%)	325 (34%)			279 (34%)	272 (33%)		
Age	74 (63-82)	73 (62-81)	0.01*	0.089	73 (61-82)	73 (62-80)	0.42	0.014
Sex (Male)	1563(57%)	563 (59%)	0.20	0.050	471(57%)	488 (59%)	0.40	0.042
NIHSS at admission								
0-3	1541(56%)	116 (12%)	Ref.	Ref.	120 (15%)	112 (13%)	Ref-	Ref-
4-10	826 (30%)	414 (43%)	<0.001	0.283	412 (50%)	392 (48%)	0.32	0.049
≥11	410 (1516%)	429 (45%)	<0.001	0.696	292 (35%)	320 (39%)	0.15	0.070
Stroke etiology								
Large-artery atherosclerosis	473 (17%)	215(23%)	<0.001	0.136	176 (21%)	188 (23%)	0.47	0.013
Small-vessel occlusion	751 (27%)	102 (11%)	<0.001	0.430	98 (12%)	95 (12%)	0.82	0.035
Cardioembolic	778 (28%)	331 (35%)	<0.001	0.141	308 (37%)	280 (34%)	0.15	0.011
Stroke location								
MCA territory	1760 (63%)	729 (76%)	<0.001	0.280	600 (73%)	612 (74%)	0.50	0.033
Cortical involvement	1358 (49%)	564 (59%)	<0.001	0.201	500 (61%)	489 (59%)	0.58	0.027
ASM treatment after ASS	100 (4%)	69 (7%)	<0.001	0.160	57 (7%)	55 (7%)	0.84	0.010

NIHSS = National Institutes of Health Stroke Scale; MCA = middle cerebral artery; ASM = anti-seizure medication; ASS= acute symptomatic seizures; SMD = standardized mean difference; * p-value is for Wilcoxon rank-sum test